Tagrisso plus chemotherapy improved progression-free survival in EGFR-positive NSCLC patients compared to placebo plus chemotherapy, with median survival of 8.4 vs. 4.4 months. Central nervous system ...

Cyramza plus Tagrisso significantly extended PFS in TKI-naïve EGFR-mutant NSCLC patients compared to Tagrisso alone, with a median PFS of 24.8 vs. 15.6 months. PFS benefits were consistent across ...

A drug combination from Johnson & Johnson outperformed AstraZeneca’s Tagrisso in slowing the worsening of newly diagnosed lung cancer. But it’ll take more than a tumor progression win to dethrone the ...

Results underscore TAGRISSO as 1st-line standard of care and backbone therapy in EGFRm lung cancer across stages WILMINGTON, Del.--(BUSINESS WIRE)-- Positive results from the final overall survival ...